查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2153365

全球病毒載體生產市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Viral Vector Production Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球病毒載體生產市場預計將從2025年的27.6億美元成長至2034年的132.8億美元，2026年至2034年的複合年成長率（CAGR）為19.06%。基因治療、細胞治療和疫苗研發計畫的蓬勃發展推動了全球病毒載體生產市場的快速擴張。病毒載體是將遺傳物質導入細胞的關鍵組成部分，在先進的生物製藥研究中不可或缺。基因治療臨床試驗的增加和法規核准的不斷擴大，顯著提升了病毒載體的生產需求。

推動這一成長的因素包括載體工程技術的進步、生產製程規模化的提升以及製藥公司的大力投資。罕見遺傳疾病和癌症發生率的上升也進一步促進了市場擴張。此外，政府資助以及生物技術公司與合約開發組織（CDO）之間的策略合作正在增強全球產能。

隨著個人化醫療逐漸成為主流，市場預計將加速成長。自動化、模組化生產設施以及上下游製程的創新將提高效率並降低成本。隨著法律規範的不斷改進以支持先進療法，病毒載體生產將繼續成為下一代生物製藥開發的基石。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球病毒載體生產市場：依適應症分類

  • 市場分析、洞察與預測
  • 癌症
  • 遺傳性疾病
  • 感染疾病
  • 其他疾病

第5章：全球病毒載體生產市場：依應用分類

  • 市場分析、洞察與預測
  • 基因治療
  • 疫苗學

第6章：全球病毒載體生產市場：依病毒載體類型分類

  • 市場分析、洞察與預測
  • 腺病毒載體
  • 慢病毒載體
  • 逆轉錄病毒載體
  • 腺結合病毒載體
  • 其他病毒載體

第7章 全球病毒載體生產市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Thermo Fisher Scientific
    • Lonza
    • Catalent
    • Charles River Laboratories
    • WuXi AppTec
    • WuXi Advanced Therapies
    • Viralgen
    • Fujifilm Diosynth Biotechnologies
    • Oxford Biomedica
    • Brammer Bio
    • Andelyn Biosciences
    • Forge Biologics
    • ElevateBio BaseCamp
    • Genezen Laboratories
    • Batavia Biosciences
    • Vibalogics
    • YposKesi
    • FinVector
    • Resilience
    • Novartis Gene Therapies
簡介目錄
Product Code: VMR112112431

The global viral vector production market size is expected to reach USD 13.28 Billion in 2034 from USD 2.76 Billion in 2025, growing at a CAGR of 19.06% during 2026-2034.The Global Viral Vector Production Market is witnessing rapid expansion driven by the surge in gene therapy, cell therapy, and vaccine development programs. Viral vectors are critical components in delivering genetic material into cells, making them indispensable in advanced biopharmaceutical research. Increasing clinical trials and regulatory approvals for gene-based therapies are significantly boosting production demand.

Growth drivers include technological advancements in vector engineering, improved scalability of manufacturing processes, and strong investments from pharmaceutical companies. The rising prevalence of rare genetic disorders and cancer further supports market expansion. Additionally, government funding and strategic collaborations between biotech firms and contract development organizations enhance production capacity worldwide.

Looking ahead, the market is expected to grow at an accelerated pace as personalized medicine gains mainstream acceptance. Automation, modular manufacturing facilities, and innovations in upstream and downstream processing will improve efficiency and reduce costs. As regulatory frameworks evolve to support advanced therapies, viral vector production will remain a cornerstone of next-generation biopharmaceutical development.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Indication

  • Cancer
  • Genetic Disorders
  • Infectious Diseases
  • Other Diseases

By Application

  • Gene Therapy
  • Vaccinology

By Viral Vector Type

  • Adenoviral Vectors
  • Lentiviral Vectors
  • Retroviral Vectors
  • Adeno-Associated Viral Vectors
  • Other Viral Vectors

COMPANIES PROFILED

  • Thermo Fisher Scientific, Lonza, Catalent, Charles River Laboratories, WuXi AppTec, WuXi Advanced Therapies, Viralgen, Fujifilm Diosynth Biotechnologies, Oxford Biomedica, Brammer Bio, Andelyn Biosciences, Forge Biologics, ElevateBio BaseCamp, Genezen Laboratories, Batavia Biosciences, Vibalogics, YposKesi, FinVector, Resilience, Novartis Gene Therapies

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL VIRAL VECTOR PRODUCTION MARKET: BY INDICATION 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Indication
  • 4.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Genetic Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Other Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL VIRAL VECTOR PRODUCTION MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Application
  • 5.2. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Vaccinology Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL VIRAL VECTOR PRODUCTION MARKET: BY VIRAL VECTOR TYPE 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Viral Vector Type
  • 6.2. Adenoviral Vectors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Lentiviral Vectors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Retroviral Vectors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Adeno-Associated Viral Vectors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.6. Other Viral Vectors Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL VIRAL VECTOR PRODUCTION MARKET: BY REGION 2022-2034 (USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Indication
    • 7.2.2 By Application
    • 7.2.3 By Viral Vector Type
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Indication
    • 7.3.2 By Application
    • 7.3.3 By Viral Vector Type
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Spain
    • 7.3.9 Russia
    • 7.3.10 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Indication
    • 7.4.2 By Application
    • 7.4.3 By Viral Vector Type
    • 7.4.4 China
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 India
    • 7.4.8 Australia
    • 7.4.9 South East Asia
    • 7.4.10 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Indication
    • 7.5.2 By Application
    • 7.5.3 By Viral Vector Type
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Indication
    • 7.6.2 By Application
    • 7.6.3 By Viral Vector Type
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL VIRAL VECTOR PRODUCTION INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Thermo Fisher Scientific
    • 9.2.2 Lonza
    • 9.2.3 Catalent
    • 9.2.4 Charles River Laboratories
    • 9.2.5 WuXi AppTec
    • 9.2.6 WuXi Advanced Therapies
    • 9.2.7 Viralgen
    • 9.2.8 Fujifilm Diosynth Biotechnologies
    • 9.2.9 Oxford Biomedica
    • 9.2.10 Brammer Bio
    • 9.2.11 Andelyn Biosciences
    • 9.2.12 Forge Biologics
    • 9.2.13 ElevateBio BaseCamp
    • 9.2.14 Genezen Laboratories
    • 9.2.15 Batavia Biosciences
    • 9.2.16 Vibalogics
    • 9.2.17 YposKesi
    • 9.2.18 FinVector
    • 9.2.19 Resilience
    • 9.2.20 Novartis Gene Therapies